|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANGEL2 |
Gene summary for ANGEL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANGEL2 | Gene ID | 90806 |
| Gene name | angel homolog 2 | |
| Gene Alias | Ccr4d | |
| Cytomap | 1q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | B7Z297 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90806 | ANGEL2 | LZE2T | Human | Esophagus | ESCC | 2.60e-07 | 7.31e-01 | 0.082 |
| 90806 | ANGEL2 | LZE4T | Human | Esophagus | ESCC | 3.17e-07 | 2.34e-01 | 0.0811 |
| 90806 | ANGEL2 | LZE7T | Human | Esophagus | ESCC | 6.64e-10 | 4.00e-01 | 0.0667 |
| 90806 | ANGEL2 | LZE24T | Human | Esophagus | ESCC | 1.54e-16 | 2.52e-01 | 0.0596 |
| 90806 | ANGEL2 | P1T-E | Human | Esophagus | ESCC | 8.44e-08 | 2.67e-01 | 0.0875 |
| 90806 | ANGEL2 | P2T-E | Human | Esophagus | ESCC | 1.22e-18 | 3.60e-01 | 0.1177 |
| 90806 | ANGEL2 | P4T-E | Human | Esophagus | ESCC | 8.53e-14 | 2.01e-01 | 0.1323 |
| 90806 | ANGEL2 | P5T-E | Human | Esophagus | ESCC | 8.57e-23 | 3.57e-01 | 0.1327 |
| 90806 | ANGEL2 | P8T-E | Human | Esophagus | ESCC | 3.00e-17 | 2.98e-01 | 0.0889 |
| 90806 | ANGEL2 | P9T-E | Human | Esophagus | ESCC | 7.76e-13 | 2.07e-01 | 0.1131 |
| 90806 | ANGEL2 | P10T-E | Human | Esophagus | ESCC | 1.83e-23 | 3.93e-01 | 0.116 |
| 90806 | ANGEL2 | P11T-E | Human | Esophagus | ESCC | 1.22e-10 | 2.89e-01 | 0.1426 |
| 90806 | ANGEL2 | P12T-E | Human | Esophagus | ESCC | 7.87e-13 | 2.05e-01 | 0.1122 |
| 90806 | ANGEL2 | P15T-E | Human | Esophagus | ESCC | 5.06e-16 | 2.48e-01 | 0.1149 |
| 90806 | ANGEL2 | P16T-E | Human | Esophagus | ESCC | 1.58e-22 | 3.30e-01 | 0.1153 |
| 90806 | ANGEL2 | P17T-E | Human | Esophagus | ESCC | 8.76e-06 | 1.76e-01 | 0.1278 |
| 90806 | ANGEL2 | P19T-E | Human | Esophagus | ESCC | 1.43e-02 | 2.68e-01 | 0.1662 |
| 90806 | ANGEL2 | P20T-E | Human | Esophagus | ESCC | 1.01e-17 | 2.56e-01 | 0.1124 |
| 90806 | ANGEL2 | P21T-E | Human | Esophagus | ESCC | 4.04e-17 | 3.35e-01 | 0.1617 |
| 90806 | ANGEL2 | P22T-E | Human | Esophagus | ESCC | 1.63e-18 | 3.04e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
| GO:006101319 | Esophagus | ESCC | regulation of mRNA catabolic process | 115/8552 | 166/18723 | 5.90e-10 | 1.49e-08 | 115 |
| GO:004348719 | Esophagus | ESCC | regulation of RNA stability | 117/8552 | 170/18723 | 7.91e-10 | 1.94e-08 | 117 |
| GO:004348819 | Esophagus | ESCC | regulation of mRNA stability | 109/8552 | 158/18723 | 2.40e-09 | 5.35e-08 | 109 |
| GO:0031330111 | Esophagus | ESCC | negative regulation of cellular catabolic process | 166/8552 | 262/18723 | 5.17e-09 | 1.08e-07 | 166 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:00905033 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 35/8552 | 42/18723 | 5.35e-07 | 7.11e-06 | 35 |
| GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
| GO:1903312111 | Esophagus | ESCC | negative regulation of mRNA metabolic process | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANGEL2 | SNV | Missense_Mutation | c.1618N>G | p.Phe540Val | p.F540V | Q5VTE6 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ANGEL2 | SNV | Missense_Mutation | rs765456910 | c.950G>A | p.Arg317Gln | p.R317Q | Q5VTE6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| ANGEL2 | SNV | Missense_Mutation | novel | c.1252N>A | p.Glu418Lys | p.E418K | Q5VTE6 | protein_coding | tolerated(0.37) | benign(0.009) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| ANGEL2 | SNV | Missense_Mutation | c.947N>T | p.Arg316Met | p.R316M | Q5VTE6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ANGEL2 | SNV | Missense_Mutation | c.848N>T | p.Arg283Ile | p.R283I | Q5VTE6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ANGEL2 | insertion | Frame_Shift_Ins | novel | c.744_745insTTACATGGCTATTTGAAAACCTTGGATGATCCAGTACCCTC | p.Arg249LeufsTer34 | p.R249Lfs*34 | Q5VTE6 | protein_coding | TCGA-A8-A08X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | PD | ||
| ANGEL2 | SNV | Missense_Mutation | novel | c.1411N>G | p.His471Asp | p.H471D | Q5VTE6 | protein_coding | deleterious(0.05) | possibly_damaging(0.906) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ANGEL2 | SNV | Missense_Mutation | rs765456910 | c.950G>A | p.Arg317Gln | p.R317Q | Q5VTE6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| ANGEL2 | SNV | Missense_Mutation | c.430N>C | p.Glu144Gln | p.E144Q | Q5VTE6 | protein_coding | tolerated(0.31) | benign(0.043) | TCGA-AG-3883-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ANGEL2 | SNV | Missense_Mutation | c.885A>C | p.Lys295Asn | p.K295N | Q5VTE6 | protein_coding | tolerated(0.47) | benign(0.03) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |